Eisenmenger Syndrome: Comprehensive Research Report

1. Disease Information

Overview. Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). It describes the end-stage physiology that develops when a large, long-standing, unrestricted communication between the systemic and pulmonary circulations (at the aortopulmonary, ventricular, or atrial level) produces chronic high-flow/high-pressure exposure of the pulmonary vasculature, driving progressive pulmonary vascular remodeling, severe pulmonary vascular resistance (PVR) elevation, and eventual reversal of the shunt from left-to-right to right-to-left (or bidirectional), producing chronic systemic hypoxemia and cyanosis. First described by Paul Wood in 1958, ES is defined operationally as "pulmonary hypertension due to a high pulmonary vascular resistance with reversed or bidirectional shunt" occurring in the presence of a non-restrictive aortopulmonary, ventricular, or atrial communication (Banerjee & Opotowsky, 2024, PMID:39711759).

Key identifiers: - MONDO: MONDO:0019944 (Eisenmenger syndrome/complex) - Orphanet: ORPHA:97214 - ICD-10-CM: I27.83 (Eisenmenger's syndrome — pulmonary heart disease; code also the underlying defect, e.g., Q21.8 "Eisenmenger's defect," or the specific septal defect code) - MeSH: D004466 (Eisenmenger Complex) - NCIT candidate treatment-action anchor: NCIT:C15986 (Pharmacotherapy), NCIT:C15329 (Surgical Procedure) — for downstream annotation of PAH-targeted drugs and transplantation

Synonyms/alternative names: Eisenmenger complex; Eisenmenger reaction; Eisenmenger physiology; pulmonary hypertension due to congenital systemic-to-pulmonary shunt with reversed/bidirectional shunt.

Nature of evidence base: Because ES is a rare, heterogeneous, acquired physiologic end-state of multiple distinct congenital cardiac lesions (rather than a single monogenic disorder), the literature is predominantly aggregated disease-level and cohort-level clinical evidence — multicenter and single-center adult congenital heart disease (ACHD) registries (e.g., the Euro Heart Survey, UK/Royal Brompton cohorts, COMPERA-CHD), randomized controlled trials of PAH-targeted therapy (e.g., BREATHE-5, EIGER, the bosentan-sildenafil combination RCT), and case series/case reports for rarer complications (pregnancy, transplantation). There is essentially no individual-patient EHR-derived "N-of-1" data source specific to ES as such; genetic data (e.g., BMPR2 mutation carriage) come from smaller mechanistic/candidate-gene cohorts nested within PAH-CHD research rather than population biobanks.

2. Etiology

2a. Disease Causal Factors (mechanistic/anatomic)

ES is not itself a primary genetic disease but the pathophysiological consequence of an untreated congenital systemic-to-pulmonary shunt. The causal chain is: 1. A non-restrictive congenital cardiac communication (VSD, ASD, AVSD, PDA, truncus arteriosus, or a complex/univentricular lesion with unobstructed pulmonary flow) permits chronic left-to-right shunting. 2. Persistently elevated pulmonary blood flow and/or pressure produces shear-stress-mediated pulmonary endothelial dysfunction, triggering progressive pulmonary vascular remodeling (vasoconstriction → medial hypertrophy → intimal proliferation/fibrosis → in situ thrombosis → plexiform arteriopathy). 3. Rising PVR eventually equals or exceeds systemic vascular resistance, reversing (or making bidirectional) the shunt — the defining moment of "Eisenmenger physiology" — producing chronic hypoxemia/cyanosis (PMC11658362, PMID:39711759; StatPearls NBK507800).

Lesion-specific risk of progression to ES (StatPearls; JACC 2008 review, PMID:19245962): - Truncus arteriosus: nearly all unrepaired cases progress - Large unrepaired VSD: ~50% (aortopulmonary or ventricular-level shunts overall 52–53% in Euro Heart Survey data) - Large unrepaired PDA: substantial risk, especially with continuous high-pressure exposure - Large unrepaired ASD: only ~9–10% (because pressure, not just flow, is transmitted less directly at the atrial level) — this lower-penetrance group is where a genetic susceptibility factor (e.g., BMPR2) is thought to matter most, since hemodynamic stress alone is often insufficient (ScienceDirect, PMID:27002414).

2b. Risk Factors

Genetic risk factors: - BMPR2 mutations — heterozygous loss-of-function variants in the TGF-β/BMP type II receptor gene, the classic cause of heritable/idiopathic PAH, are also found at increased rate in PAH-CHD/Eisenmenger cohorts. One cohort found a 12.6% BMPR2 mutation rate in "repaired" CHD-associated pulmonary vascular disease patients (i.e., those who develop PAH despite/after defect closure), with missense variants predominating and a higher detection rate in females and repaired patients (Zhu et al., PMID:27002414). BMPR2 is proposed as "a potential predisposing genetic risk factor" that lowers the threshold for hemodynamic-stress-induced pulmonary vascular disease, but the relationship is not absolute — ASD-associated Eisenmenger physiology can occur without any detectable BMPR2 mutation, implying other genetic contributors (PMID:17102831). - Other BMP/TGF-β pathway genes implicated in PAH broadly (and plausibly relevant modifiers in PAH-CHD): ACVRL1/ALK1, ENG (endoglin), SMAD1, SMAD4, SMAD9, SMAD5, SOX17 — variants (including de novo changes) have been reported in APAH-CHD cohorts (Springer Pediatric Cardiology review, 2025). - Trisomy 21 (Down syndrome, HGNC gene dosage effect, not single-gene) — a well-established genetic factor that accelerates progression to pulmonary vascular obstructive disease/Eisenmenger physiology independent of lesion type, historically producing ES at much younger ages and higher rates when surgery was delayed (PMID:27325590). - Standard clinical genetic screening for suspected heritable PAH contribution focuses on sequencing BMPR2, ALK1 (ACVRL1), Endoglin (ENG), and SMAD9.

Environmental/clinical risk factors: - Delayed or absent surgical repair of the underlying shunt lesion — the single largest modifiable risk factor. Repair within the first ~2 years of life largely prevents ES. - Post-tricuspid (ventricular-level or great-vessel-level) shunt location vs. pre-tricuspid (atrial-level) — post-tricuspid shunts transmit pressure directly to the pulmonary circuit and confer much higher ES risk. - Limited access to healthcare/diagnostic services — geographic/socioeconomic disparity is a major real-world driver; ES is now largely a disease of resource-limited settings, since early detection and closure have reduced its prevalence by ~50% over 50 years in the developed world (PMID:28566473). - High altitude residence — chronic hypoxic pulmonary vasoconstriction is understood to exacerbate pulmonary vascular disease progression (cited as an aggravating/avoidance factor in management guidance; StatPearls NBK507800). - Female sex and repaired-CHD status correlate with higher detected BMPR2 mutation rates in the cited cohort, suggesting a possible sex-genetic interaction, though data are limited.

2c. Protective Factors

Early corrective/palliative cardiac surgery (within the first 1–2 years of life) is the dominant protective intervention and has driven the measured decline in ES incidence in high-resource countries.
Improved perinatal/pediatric screening (prenatal echocardiography, newborn pulse-oximetry screening) enabling earlier defect detection.
No specific protective genetic variant has been characterized for ES to date (unlike some diseases with described protective alleles); this remains an evidence gap.

2d. Gene-Environment Interactions

The clearest documented gene-environment interaction is that hemodynamic stress (the "environmental"/mechanical exposure of chronic shunt flow) is necessary but not sufficient to cause severe irreversible pulmonary vascular disease in many patients — a genetic susceptibility factor (BMPR2 or other BMP-pathway variant) appears to lower the flow/pressure threshold required to trigger irreversible remodeling, explaining why only a minority of patients with a given anatomic lesion (e.g., ~9–53% depending on lesion type) progress to ES despite similar shunt anatomy (PMID:27002414, PMID:17102831). Down syndrome (a genetic dosage state) similarly interacts with shunt-lesion "exposure" to accelerate the same final pathway.

3. Phenotypes

Symptoms / Clinical Signs (HP-mappable)

Table (click to expand)

Phenotype	Suggested HPO term	Frequency/notes
Exertional dyspnea	HP:0002875 (Exertional dyspnea)	Most frequent presenting symptom
Central cyanosis	HP:0007204 (Central cyanosis) / HP:0000961 (Cyanosis)	Cardinal, progressive feature; onset usually childhood–young adulthood as shunt reverses
Digital clubbing	HP:0100759 (Nail clubbing)	Common, more pronounced in lower extremities with PDA-associated ES ("differential clubbing/cyanosis")
Syncope	HP:0001279 (Syncope)	Poor prognostic marker at presentation
Palpitations	HP:0001962 (Palpitations)	Reflects atrial/ventricular arrhythmia
Hemoptysis	HP:0002105 (Hemoptysis)	From pulmonary infarction, vessel rupture, or coagulopathy; historically a leading cause of death, now 5th most common (post-DTT era)
Fatigue/lethargy	HP:0012378 (Fatigue)	Nonspecific but near-universal
Chest pain	HP:0100749 (Chest pain)	Can reflect pulmonary infarction or ischemia
Right heart failure signs (edema, ascites, hepatomegaly)	HP:0000969 (Edema), HP:0001541 (Ascites), HP:0002240 (Hepatomegaly)	Progressive/late-stage; leading contemporary cause of death
Headache/dizziness/visual changes (hyperviscosity)	HP:0002315 (Headache), HP:0002321 (Vertigo)	From secondary erythrocytosis/hyperviscosity
Gout	HP:0002804 (Joint hyperflexibility — not exact; better: HP:0001997 Gout)	From hyperuricemia (increased RBC turnover)
Cholelithiasis	HP:0001081 (Cholelithiasis)	From chronic hyperbilirubinemia (hemolysis/RBC turnover)
Hypertrophic osteoarthropathy	HP:0040217 (Hypertrophic pulmonary osteoarthropathy candidate)	Associated with chronic cyanosis
Stroke/TIA	HP:0001297 (Stroke)	Paradoxical embolism or thrombotic; cerebral abscess also reported
Brain abscess	HP:0100738 (Brain abscess)	From right-to-left shunt bypassing pulmonary filtration of septic emboli
Nephropathy/proteinuria	HP:0000093 (Proteinuria)	Reported in up to 30% (proteinuria) / ~60% (albuminuria) of cyanotic patients

Onset, Severity, Progression, Frequency

Age of onset: Highly lesion-dependent. Post-tricuspid shunts (large VSD, PDA, truncus arteriosus, AVSD, especially with trisomy 21) can progress to irreversible pulmonary vascular disease and shunt reversal in infancy to early childhood; pre-tricuspid shunts (ASD) typically manifest ES only in the third or fourth decade of life or later.
Severity/progression: Progressive and generally irreversible once established; three histopathologic stages of the underlying vasculopathy (vasoconstriction → remodeling → thrombosis) parallel worsening clinical severity, culminating in NYHA functional class decline, right heart failure, and death. Overall disease course is chronic and progressive, though the rate varies widely by underlying lesion complexity.
Frequency among CHD patients: ~8% of all congenital heart disease patients develop ES; historically 17.5% (Wood, 1958) versus 1–5.7% in contemporary high-resource registries (e.g., 5.7% of 4,110 adults in the Euro Heart Survey), reflecting the impact of early surgical repair (PMID:39711759; PMID:28566473).

Quality of Life

Quality of life is markedly and disproportionately impaired compared with other cyanotic CHD groups: exercise performance and QoL are more impaired in ES than in complex cyanotic CHD with pulmonary stenosis (PMID:20439122), with peak oxygen uptake reduced ~45% and ventilatory equivalent for CO₂ ~70% higher than healthy controls. Most patients function in NYHA/WHO functional class II–III. PAH-targeted drug therapy (e.g., sildenafil) has been shown to significantly improve QoL and functional class in randomized and observational studies (PMID:20304507).

4. Genetic/Molecular Information

Causal genes (susceptibility, not strictly Mendelian-causal for the syndrome itself): - BMPR2 (HGNC:1078; OMIM 600799) — bone morphogenetic protein receptor type 2; loss-of-function/missense variants; the canonical heritable-PAH gene, also implicated as a susceptibility modifier in PAH-CHD/ES (PMID:27002414). - ACVRL1/ALK1 (HGNC:175) and ENG (HGNC:3349) — activin receptor-like kinase 1 and endoglin, both BMP9/10 co-receptor components; classically hereditary hemorrhagic telangiectasia genes, also linked to PAH. - SMAD1, SMAD4, SMAD5, SMAD9 (downstream BMP-pathway transcription factors) — variants reported in APAH-CHD, including de novo changes. - SOX17 — increasingly recognized PAH-CHD-associated gene.

Variant classification/type: Predominantly missense (dominant, likely haploinsufficiency mechanism for BMPR2); variant pathogenicity should be interpreted per ACMG/AMP criteria via ClinVar/ClinGen. Functional consequence is generally loss of function in the BMP/TGF-β signaling receptor complex, disinhibiting proliferative/anti-apoptotic signaling in pulmonary vascular smooth muscle and endothelium.

Population frequency: Rare variants; population allele frequency data should be checked against gnomAD for any specific variant before curation (no ES-specific germline founder variant has been established).

Somatic vs. germline: Germline (constitutional) — these are inherited/de novo susceptibility alleles, not somatic mutations.

Chromosomal abnormality: Trisomy 21 (Down syndrome) is the principal chromosomal risk factor, present in a substantial minority of ES patients with AVSD/VSD, and independently associated with accelerated pulmonary vascular disease.

Epigenetics: No ES-specific DNA methylation/histone signature has been well characterized in the literature reviewed; this is a knowledge gap. (Broader PAH literature does describe epigenetic dysregulation, e.g., of BMPR2 and HIF pathways, but ES-specific data are sparse — flag as KNOWLEDGE_GAP if curating.)

Suggested gene/ontology annotations: - Gene: hgnc:1078 (BMPR2), hgnc:175 (ACVRL1), hgnc:3349 (ENG), hgnc:11177 (SMAD9) - GO biological process: GO:0030510 (regulation of BMP signaling pathway), GO:0001525 (angiogenesis), GO:0003085 (negative regulation of systemic arterial blood pressure — context-dependent)

5. Environmental Information

Environmental/exposure factors: No toxin, pollutant, or occupational exposure is established as causal for ES; the "environmental" driver is fundamentally mechanical/hemodynamic (chronic high pulmonary flow/pressure from the unrepaired shunt) rather than a chemical or infectious agent.
Lifestyle factors relevant to management (not causation): Dehydration, isometric exercise, high-altitude exposure, and iron deficiency are all specifically flagged in clinical guidance as conditions to avoid because they exacerbate hyperviscosity/hypoxemia physiology in established ES (StatPearls NBK507800). Suggested ECTO terms would apply to "exposure to high altitude" as an exacerbating (not causal) factor.
Infectious agents: Not causal, but infective endocarditis is a major secondary complication given the intracardiac shunt and turbulent flow, with risk of septic paradoxical embolization to the brain (abscess) or systemic circulation because right-to-left shunting bypasses the normal pulmonary filtration of septic emboli.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream)

Trigger (MOLECULAR/TISSUE scale): Chronic elevated pulmonary blood flow and/or pressure from a non-restrictive systemic-to-pulmonary shunt imposes abnormal shear stress on the pulmonary vascular endothelium.
Endothelial dysfunction (MOLECULAR/CELLULAR): Dysfunctional pulmonary-artery endothelial cells show decreased production of prostacyclin (PGI2) and endogenous nitric oxide (via eNOS dysfunction), together with increased endothelin-1 (ET-1) production — an imbalance that favors vasoconstriction and smooth-muscle proliferation. Elevated thromboxane A2, platelet activation, and increased intrinsic elastase and vascular endothelial growth factor (VEGF) production further drive pathological remodeling (JACC 2008 review PMID:19245962; PMC11658362).
Vascular remodeling (TISSUE): Progressive structural changes follow the classic Heath-Edwards histopathological grading (1958):
Grade I: medial hypertrophy of small muscular arteries/arterioles
Grade II: + intimal cellular proliferation (smooth muscle migration to subendothelium)
Grade III: + advanced medial thickening, progressive intimal fibrosis, arteriolar obliteration
Grade IV: plexiform lesions — focal proliferation of endothelial-lined channels within dilated arterial segments
Grade V: complex plexiform, angiomatous, and cavernous lesions with hyalinizing intimal fibrosis
Hemodynamic consequence (ORGANISM): Rising pulmonary vascular resistance eventually equals/exceeds systemic vascular resistance, reversing the shunt from left-to-right to bidirectional/right-to-left — the defining Eisenmenger transition — producing chronic arterial hypoxemia.
Systemic downstream consequences (ORGANISM): Chronic hypoxemia triggers secondary/compensatory erythrocytosis (renal erythropoietin-driven), which can be blunted by iron deficiency; hyperviscosity with thrombotic/hemorrhagic diathesis; multiorgan effects including renal dysfunction (proteinuria/albuminuria, reduced GFR), gout (hyperuricemia from increased cell turnover), cholelithiasis (hyperbilirubinemia), hypertrophic osteoarthropathy, and neurologic events (paradoxical embolism, cerebral abscess, hemorrhagic/ischemic stroke).
Cardiac remodeling and arrhythmia (TISSUE/ORGANISM): Chronic right ventricular pressure/volume overload leads to right heart failure over time; atrial arrhythmias (notably atrial fibrillation, conferring an ~11.45-fold increased sudden cardiac death risk in multivariate analysis), conduction disease, and ventricular arrhythmia contribute to sudden cardiac death — the second/third leading cause of mortality in the contemporary era (AHA/JAHA PMID via PMC7335528).

Cell types and biological processes involved

Pulmonary artery endothelial cells (CL:0002544 or general endothelial cell CL:0000115) — dysfunction is the initiating cellular lesion.
Pulmonary artery vascular smooth muscle cells (CL:0000359) — undergo hyperplasia/hypertrophy and migration into the intima.
Platelets — activation contributes to in situ thrombosis and to the bleeding/thrombosis diathesis.
Renal cells (erythropoietin-producing interstitial fibroblasts) — drive compensatory erythropoiesis.
Relevant GO biological processes: GO:0001525 (angiogenesis), GO:0043615 (astrocyte cell migration — not relevant), better: GO:0090023 (positive regulation of neutrophil chemotaxis — not relevant); most relevant: GO:0001974 (blood vessel remodeling), GO:0043491 (protein kinase B signaling — pathway adjacent), GO:0007179 (TGF-beta receptor signaling pathway, given BMPR2/ALK1 involvement), GO:0038063 (T cell extravasation — not relevant). Core recommended terms: GO:0001974 (blood vessel remodeling), GO:0007179 (transforming growth factor beta receptor signaling pathway), GO:0001525 (angiogenesis).

Suggested downstream/module conformance

This pathophysiology is closely analogous to the dismech pulmonary_vascular_remodeling module (HP:0002092, obstructive pulmonary vascular remodeling driving PAH with RV overload) and shares upstream endothelial-dysfunction biology with the general vascular-remodeling literature; ES-specific curation should model it as a CHD-triggered variant of that chain, with the shunt-reversal node as the key discriminating causal step versus idiopathic/heritable PAH.

7. Anatomical Structures Affected

Organ level: - Primary: Heart (all chambers, especially right ventricle and atria) and pulmonary arterial vasculature (UBERON:0002012 pulmonary artery; UBERON:0000948 heart) - Secondary/systemic: Kidneys (proteinuria, reduced GFR), liver/biliary tree (cholelithiasis from hyperbilirubinemia), joints (gout), bone/periosteum (hypertrophic osteoarthropathy), central nervous system (stroke, brain abscess), skin (plethora, acrocyanosis, livedo reticularis, ischemic ulceration), bone marrow (erythroid hyperplasia). - Body systems: Cardiovascular (primary), respiratory, renal, hepatobiliary, musculoskeletal, hematologic, neurologic.

Tissue/cell level: - Pulmonary arterial media, intima, and adventitia (site of Heath-Edwards remodeling grades I–V) - Right ventricular myocardium (hypertrophy/fibrosis from chronic pressure overload) - Bone marrow erythroid precursors (erythrocytosis)

Subcellular level (GO Cellular Component): - Endothelial cell plasma membrane (site of eNOS, ET-1 receptor signaling) - Mitochondria (implicated ROS accumulation contributing to endothelial dysfunction)

Localization: Bilateral, diffuse pulmonary vascular involvement (not lateralized); underlying cardiac defect location varies (septal — ventricular/atrial — vs. great vessel level for PDA/truncus arteriosus).

8. Temporal Development

Onset pattern: Insidious and progressive, beginning with an asymptomatic left-to-right shunt phase in infancy, transitioning through a variable latency period to shunt reversal. Onset of overt cyanosis/ES physiology ranges from infancy (post-tricuspid, high-pressure lesions, especially with trisomy 21) to the third or fourth decade (pre-tricuspid ASD-type lesions).
Stages: (1) Left-to-right shunt with normal/mildly elevated PVR; (2) progressive pulmonary vascular remodeling with rising PVR (potentially still surgically correctable "window" period); (3) fixed elevated PVR with bidirectional shunting (transitional); (4) established Eisenmenger physiology with right-to-left shunting and cyanosis (surgical correction now contraindicated).
Progression rate: Variable — lesion type and presence of accelerating factors (trisomy 21, larger defect, genetic susceptibility) determine rate; once ES is established, disease is chronic and progressive with intermittent stability punctuated by complications (arrhythmia, hemoptysis, heart failure decompensation).
Critical period for intervention: Cardiac repair in the first 2 years of life is the key window to prevent ES; beyond a certain threshold of fixed pulmonary vascular disease, defect closure becomes contraindicated because removing the "pop-off" right-to-left shunt in the face of severe fixed PVR precipitates acute right heart failure.
Remission: No spontaneous remission described; "treat and repair" (aggressive PAH-targeted therapy followed by defect closure in selected reversible cases) shows good short/medium-term outcomes in case series but lacks long-term outcome data and cannot yet be systematically recommended (PMID:39711759).

9. Inheritance and Population

Epidemiology: - ~8% of all CHD patients develop ES overall; historically 17.5% (Wood 1958 cohort) vs. 1–5.7% contemporary (Euro Heart Survey: 5.7% of 4,110 adults). - Orphanet prevalence estimate: 1–9 per 1,000,000 (ultra-rare). - By lesion: 52–53% of large aortopulmonary/ventricular-level shunts progress to ES vs. only ~9–10% of large atrial-level shunts. - Prevalence has declined ~50% over the past 50 years in developed countries due to early surgical repair (PMID:28566473), while remaining a larger relative burden in resource-limited regions with delayed diagnosis/access to cardiac surgery (e.g., a Yunnan, China pediatric CHD cohort study, PMID:35522268).

Inheritance pattern: ES itself is not a single-gene Mendelian disorder — it is an acquired physiologic consequence of an underlying (usually sporadic) congenital cardiac malformation, modified by susceptibility genetics (BMPR2 and related BMP-pathway variants, generally autosomal dominant with incomplete penetrance when causal for heritable PAH) and by chromosomal factors (trisomy 21). - Penetrance: Incomplete for BMPR2-type susceptibility variants — most CHD patients with a given lesion do NOT develop ES even without repair, implying gene-environment/dose interaction. - Founder effects / consanguinity / carrier frequency: Not well established specific to ES; the underlying CHD lesions themselves (e.g., AVSD in trisomy 21) have their own population genetics.

Population demographics: - Sex ratio: Reported as approximately equal (males and females equally affected), per NORD/GARD summaries, though BMPR2 mutation detection rate was higher in females in one cohort (PMID:27002414) and pregnancy-specific complications obviously affect female patients disproportionately in clinical impact. - Geographic distribution: Disproportionately represents populations with limited access to pediatric cardiac surgery — a "disease of health system gaps" in the modern era. - Age distribution: Adult survivors span young adulthood through middle age; median survival substantially reduced relative to the general population (see Section 11).

10. Diagnostics

Clinical/initial workup: - History and physical exam (cyanosis, clubbing, signs of right heart failure); note that loud murmurs may be absent because equalized right/left ventricular pressures minimize turbulent flow across the shunt — an important diagnostic pitfall (StatPearls NBK507800). - Pulse oximetry (resting and with exercise) - Chest radiograph, ECG, pulmonary function tests - Complete blood count and iron studies (to characterize secondary erythrocytosis and iron status) - Renal function, uric acid (annual monitoring recommended) - BNP/NT-proBNP (validated prognostic biomarker, more reliable than echocardiographic RVEF alone for prognosis; PMC5841908)

Imaging: - Echocardiography is the mainstay noninvasive tool: depicts the underlying anatomic lesion, shunt site/direction (color Doppler demonstrating right-to-left or bidirectional flow), pulmonary artery pressure estimation, right heart size/function (e.g., TAPSE <15 mm associated with adverse outcomes). - Cardiac MRI: assesses RV size/function and myocardial fibrosis — native T1/extracellular volume (ECV) mapping; an ECV threshold of ~29.0% discriminated high-risk from lower-risk patients (AUC 0.857) in one cohort. - Right heart catheterization remains the gold-standard confirmatory test, providing direct measurement of pulmonary artery pressure, PVR, saturations at each chamber, and (where relevant) pulmonary vasoreactivity testing to assess for any residual operability.

Genetic testing: Not routine for sporadic ES, but consider sequencing BMPR2, ACVRL1 (ALK1), ENG, SMAD9 when heritable PAH is suspected (e.g., family history of PAH, disproportionate severity relative to lesion, or ASD-type ES without adequate hemodynamic explanation) — a scenario explicitly documented in case reports (e.g., PMC5742392, genetic analysis in a patient with severe PAH and ASD undergoing lung transplantation).

Differential diagnosis: Other causes of pulmonary hypertension/right-to-left shunting must be excluded, including connective tissue disease (scleroderma, MCTD, SLE)-associated PAH, chronic viral infection (HIV, hepatitis B/C)-associated PAH, and idiopathic/heritable PAH without a structural shunt.

Screening: No population screening program exists for ES specifically; prevention operates through prenatal and neonatal CHD screening (fetal echocardiography, newborn pulse-oximetry screening for critical CHD) that enables early corrective surgery before irreversible pulmonary vascular disease develops.

11. Outcome/Prognosis

Survival: - Contemporary cohort data (adjusting for prior survivorship biases): 57% 10-year survival in the overall ES cohort and 34% 10-year survival in patients naïve to disease-targeting PAH therapy (PMC11658362/PMID:39711759). - Other reported figures: 98% at 1 year, 77% at 5 years, 58% at 10 years in one series; survival to age 40/50/60 of 94%/74%/52% in another. - Historical estimates (pre-modern-therapy era): ~70–80% 10-year survival, 42% 25-year survival. - Median survival is reduced by approximately 20 years compared with the general population, and is worst in patients with complex/multiple lesions. - Notably, ES patients have better survival than adults with idiopathic PAH with comparable hemodynamics, attributed to the protective "pop-off" effect of the right-to-left shunt decompressing the right ventricle.

Causes of death (contemporary/disease-targeted-therapy era, in descending order): 1. Right heart failure (leading cause, unchanged across eras) 2. Sudden cardiac death 3. Arrhythmia 4. Hemoptysis (declined from 3rd to 5th most common with modern management) 5. Hemorrhage (~7.3% of known deaths); thromboembolism ~8.3% of known deaths

Predictors of poor prognosis: History of syncope, elevated mean right atrial pressure (≥8 mmHg), systemic arterial desaturation <85%, older age, pre-tricuspid shunt location, low resting SpO2, absence of sinus rhythm, pericardial effusion, reduced 6-minute walk distance, atrial fibrillation (11.45-fold increased SCD risk), QRS duration ≥120 ms (2.06-fold increased SCD risk), complete heart block, right bundle branch block, right atrial enlargement, elevated NT-proBNP, TAPSE <15 mm, low serum albumin/potassium, high cardiac MRI ECV (>29%).

Morbidity/QoL: Substantially reduced exercise capacity (peak VO2 ~45% lower than controls) and QoL, worse than in other complex cyanotic CHD groups; complications include thromboembolic and hemorrhagic events, renal impairment (proteinuria in up to 30%, albuminuria up to 60% of cyanotic patients), gout, cholelithiasis, hypertrophic osteoarthropathy, and neurological events.

Special outcome context — pregnancy: Absolute contraindication to pregnancy; maternal mortality 30–50% (up to 65% with cesarean section), with 70% of deaths occurring in the postpartum period (days 2–30) or peripartum; major causes include hypovolemia, thromboembolism, and preeclampsia.

Transplantation outcomes: Heart-lung transplantation provides the best outcomes among transplant strategies for VSD-associated ES (1-, 5-, 10-year survival of 72.6%, 51.3%, 27.6%); for ASD-associated ES, bilateral lung transplant with cardiac defect repair may offer superior outcomes to combined heart-lung transplant. Median survival post-transplant: 7.4 years (heart-lung) vs. 1.1 years (isolated lung transplant, per one comparative study) — though these figures should be interpreted cautiously given selection bias in small cohorts.

12. Treatment

Pharmacotherapy (PAH-targeted "disease-targeting therapy," DTT)

Endothelin receptor antagonists (ERAs): Bosentan — demonstrated in the BREATHE-5 RCT to significantly improve hemodynamics and exercise capacity without worsening oxygen saturation in WHO FC III ES patients (short- and long-term). Macitentan (MAESTRO trial) showed no clear benefit in less advanced disease.
PDE-5 inhibitors: Sildenafil and tadalafil — improve exercise capacity, functional class, hemodynamics, and QoL (PMID:20304507).
Prostanoids: Inhaled iloprost (EIGER study, PMID:24012036) improves 6MWD, QoL, RV function; IV epoprostenol and subcutaneous treprostinil improve hemodynamics/saturation/exercise capacity; selexipag shows benefit in case series.
Soluble guanylate cyclase stimulator: Riociguat — no ES-specific RCT, but subgroup PAH-CHD data show sustained 2-year improvement.
Combination therapy (e.g., bosentan + sildenafil, RCT PMID via academic.oup.com/eurheartj/31/9/1124): registry data show improved survival on dual therapy vs. monotherapy, though confounded by indication in observational studies.
Heart failure adjuncts: No proven mortality benefit for digoxin, ACE inhibitors, or ARBs; beta-blockers show a benefit approaching statistical significance; SGLT2 inhibitors/ARNi/MRA remain unstudied in ES specifically.
Anticoagulation: Not routinely recommended absent a specific thromboembolic indication, given the coexisting bleeding diathesis; no demonstrated survival benefit.

Advanced/procedural therapies

Intrathoracic organ transplantation (heart-lung or bilateral lung + defect repair) — the only intervention that can meaningfully improve survival/QoL in advanced disease, though limited by donor availability and surgical risk (higher perioperative bleeding).
"Treat and repair" strategy — aggressive PAH-targeted medical therapy followed by surgical defect closure in carefully selected, hemodynamically responsive patients; promising early/medium-term case-series outcomes but not yet a standard, systematically recommended pathway.
Surgical closure of the underlying defect is contraindicated once severe, fixed (non-reversible) PAH/Eisenmenger physiology is established, since the shunt is protectively decompressing the right ventricle.

Supportive care

Correction of iron deficiency (careful — avoid routine venesection/phlebotomy, which worsens iron deficiency and increases stroke risk despite historical practice); phlebotomy/apheresis reserved for hemoglobin >22 g/dL with confirmed hyperviscosity symptoms after excluding dehydration/other mimics.
Endocarditis prophylaxis, IV line air filters, avoidance of dehydration/isometric exercise/high altitude/iron deficiency.
Exercise training as an adjunct to optimal medical therapy — shown safe and beneficial for 6MWD, QoL, peak VO2, and symptoms in the PAH-CHD/ES population.
Genetic counseling for families where a heritable PAH-pathway variant is identified.

Experimental

Ongoing trials of macitentan (NCT01739400, long-term safety/tolerability) and other agents in ES-specific populations, tracked via ClinicalTrials.gov.

Suggested NCIT treatment terms

NCIT:C15986 (Pharmacotherapy) as the generic action, with therapeutic_agent bound to CHEBI terms for bosentan, sildenafil, tadalafil, iloprost, epoprostenol, treprostinil, selexipag, riociguat, macitentan.
NCIT:C15289 (Organ Transplantation) for heart-lung/lung transplantation.
NCIT:C15329 (Surgical Procedure) for defect closure (in the pre-Eisenmenger or "treat-and-repair" window only).

13. Prevention

Primary prevention: Timely surgical or catheter-based closure of the underlying congenital shunt lesion, ideally within the first 1–2 years of life, before irreversible pulmonary vascular remodeling occurs. This is by far the most effective preventive strategy and underlies the observed ~50% decline in ES prevalence over 50 years in resource-rich settings.
Secondary prevention/early detection: Prenatal fetal echocardiography and newborn pulse-oximetry screening for critical CHD enable earlier diagnosis and timely surgical referral, particularly important in high-risk groups such as infants with Down syndrome and AVSD, where the historic progression rate to ES fell from 53% (1950s/60s birth cohort) to 0.5% (2000–2009 birth cohort) with improved early surgical intervention (ResearchGate/PMID:27325590 summary).
Tertiary prevention (in established ES): Endocarditis prophylaxis, avoidance of precipitants (dehydration, high altitude, isometric exercise, iron deficiency), correction of iron deficiency without inappropriate venesection, annual laboratory monitoring (CBC, iron studies, renal function, uric acid), pregnancy avoidance/contraception counseling, and early initiation of PAH-targeted therapy to reduce sudden cardiac death and heart failure risk.
Genetic counseling: Recommended for families with a heritable PAH-pathway variant (BMPR2 or related gene) identified in a proband, given autosomal dominant inheritance with incomplete penetrance.
Public health: Improving global access to pediatric cardiac surgery and diagnostic imaging is explicitly identified in the literature as the single most impactful public-health lever, since "the majority of children at risk globally will have a reparable heart defect" and timely access "would eliminate the vast majority of suffering, disability, and death from Eisenmenger syndrome" (StatPearls NBK507800).

14. Other Species / Natural Disease

Taxonomy: Naturally occurring "Eisenmenger physiology" (shunt reversal with pulmonary hypertension) is well documented in domestic dogs (Canis lupus familiaris, NCBITaxon:9615) and cats, most classically in the context of patent ductus arteriosus (PDA) that goes unrecognized/untreated.
Natural disease/veterinary relevance: In dogs with bidirectionally or continuously right-to-left shunting PDA, "Eisenmenger's (patho-)physiology" is the standard veterinary term for the same shear-stress-driven pulmonary vascular remodeling → shunt reversal sequence described in humans, with clinical presentation of cyanosis, polycythemia, and congestive heart failure (Greet et al., JVIM 2021; dvm360 review). One reported dog colony showed pulmonary hypertension and shunt reversal developing within the first few weeks of life, closely paralleling the accelerated human pediatric (e.g., trisomy 21) phenotype, making canine PDA populations a naturally occurring comparative model.
Comparative biology: The pathophysiological cascade (endothelial shear stress → reactive vasoconstriction → medial hypertrophy → intimal proliferation → shunt reversal) is conserved between species, supporting the general mechanistic model. Differential clubbing/cyanosis (more pronounced in caudal versus cranial body regions) is a distinguishing clinical sign in PDA-associated reverse shunting in both species, reflecting the anatomic level of the shunt relative to the origin of the great vessels.
Zoonotic potential: None — this is a hemodynamic/structural disease, not transmissible.

15. Model Organisms

In vivo surgical/flow models (primary experimental system used):
Rodent aortocaval fistula (ACF) model — a surgically created communication between the abdominal aorta and inferior vena cava in rats/mice reproduces the physiological and pathological hallmarks of CHD-associated PAH, including volume-overload-driven pulmonary vascular remodeling and matrix synthesis changes consistent with cyclic-stretch-mediated injury (PMC5870112; PMID:32630068). This is presented in the literature as a reliable platform for studying shunt-associated PAH mechanistically, though it models flow/volume overload generally rather than a specific congenital cardiac lesion.
This model is also used more broadly as a volume-overload congestive heart failure/cardiac hypertrophy model (Abassi et al., 2011), so findings related purely to cardiac remodeling (versus pulmonary vascular remodeling specifically) require careful interpretation.
Naturally occurring animal disease (see Section 14): Client-owned dogs with untreated/late-diagnosed PDA developing spontaneous Eisenmenger physiology represent a naturally occurring, non-induced comparative model, valuable because it arises without artificial surgical creation of the shunt and may better capture developmental/chronic aspects of pulmonary vascular remodeling.
Limitations: No established genetically engineered mouse model (e.g., conditional Bmpr2 knockout combined with a surgical shunt) specific to Eisenmenger-type PAH-CHD was identified in this search; most mechanistic PAH mouse genetics (Bmpr2+/- mice, Sugen/hypoxia models) model idiopathic/heritable PAH rather than CHD-shunt-driven PAH specifically, and translational fidelity to the shunt-reversal endpoint of true Eisenmenger physiology has not been systematically validated — this is a candidate HUMAN_MODEL_MISMATCH consideration for curation (rodent flow/volume-overload models reproduce vascular remodeling features but not the full congenital developmental context, and canine natural disease, while anatomically faithful, has not been mechanistically profiled to the same molecular depth as rodent models).
Applications: ACF and related shunt models are primarily used to study flow-mediated endothelial shear stress signaling, extracellular matrix remodeling, and candidate therapeutic responses (e.g., testing PAH-targeted drugs in a shunt-flow context) rather than to model the full multi-decade natural history or genetic susceptibility (BMPR2) interaction seen in humans.

Summary of Key Ontology Term Suggestions for Curation